Search clinical trials for: Epoetin alfa or beta

Total 865 results

Hoffmann-La Roche

Completed

COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.

Anemia

Australia
GlaxoSmithKline

Completed

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)

Anaemia

Korea, Republic of, Russian Federation, Spain, United States, Australia, United Kingdom, Brazil, Italy, Argentina, Poland, Romania, France, Canada
First Affiliated Hospital Xi'an Jiaotong University
Xijing Hospital; Shaanxi Provincial People's Hospital; Second Affiliated Hospital... and other collaborators

Unknown

Effect of Erythropoietin in Premature Infants on White Matter Lesions and Neurodevelopmental Outcome

Cerebral Palsy | Intracranial Hemorrhages | Premature Infants | Periventricular Leukomalacia

China
Centre Hospital Regional Universitaire de Limoges

Completed

Epoetin Beta in Treating Fatigue and Anemia in Patients Receiving Palliative Care for Malignant Solid Tumors

Fatigue | Anemia | Unspecified Adult Solid Tumor, Protocol Specific

France
University of Washington
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Preterm Erythropoietin Neuroprotection Trial (PENUT Trial) (PENUT)

Extreme Prematurity

United States
Shahid Beheshti University of Medical Sciences
Pooyesh Darou

Completed

Erythropoietin Effect on Ischemic_ Reperfusion Injury in Coronary Artery Bypass Graft Surgery

Myocardial Ischemic Reperfusion Injury

Iran, Islamic Republic of
University of Zurich
Swiss National Science Foundation

Active, not recruiting

Erythropoietin for the Repair of Cerebral Injury in Very Preterm Infants (EpoRepair)

Intraventricular Hemorrhage of Prematurity

Switzerland, Austria
Hoffmann-La Roche

Completed

A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic Nephropathy

Anemia

India
Institut du Cancer de Montpellier - Val d'Aurelle

Terminated

Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors (PLATON)

Anemia | Unspecified Adult Solid Tumor, Protocol Specific

France
University of Zurich

Unknown

Non-erythroid Effects of Erythropoietin on Cognitive Function and Exercise Capacity in Humans

Healthy

Switzerland
Hoffmann-La Roche

Completed

A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)

Chronic Renal Anemia

Belgium, Brazil, United Kingdom, Serbia, Spain, Germany, Korea, Republic of, Turkey, Lithuania, Italy, Czechia, Argentina, Australia, Croatia, France, Greece, Israel, Malaysia, Mexico, Panama, Philippines, Poland, Russian Federation, ... and more
Hoffmann-La Roche

Completed

A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

Thailand
Hoffmann-La Roche

Completed

A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors

Anemia

Spain
JW Pharmaceutical

Completed

Study of Erythropoietin (EPO) Administration Schedule

Chronic Renal Failure | Anaemia

Korea, Republic of
Sheri Kashmir Institute of Medical Sciences

Completed

Neuroprotective Role of Erythropoietin in Perinatal Asphyxia

Perinatal Asphyxia

India
Hoffmann-La Roche

Terminated

A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.

Anemia

United States
Hospital de Clinicas de Porto Alegre
Oswaldo Cruz Foundation; Rio Grande do Sul State Health Department - SES/RS

Completed

Efficacy Study of Two Formulations of Erythropoietin

Comparison of the Efficacy of Two Formulations of Epoetin in Patients Undergoing Hemodialysis
Hoffmann-La Roche

Completed

A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy

Anemia

Italy
Hoffmann-La Roche

Terminated

A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B

Anemia

Venezuela
Hoffmann-La Roche

Terminated

A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy

Anemia

Venezuela
Hoffmann-La Roche

Completed

A Study of Mircera for the Treatment of Anemia in Dialysis Patients

Anemia

Spain, United States, Czech Republic, Canada, Greece, Switzerland, Thailand, Poland, Russian Federation, Sweden, South Africa, Norway, Brazil
Megalabs
Azidus Laboratories

Not yet recruiting

Comparative Study of Two Recombinant Human Erythropoietin Products on Chronic Kidney Disease Patients (ENCASE)

Anemia of Chronic Kidney Disease

Uruguay
M.D. Anderson Cancer Center

Completed

Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy

Leukemia

United States
Hoffmann-La Roche

Completed

A Study of NeoRecormon (Epoetin Beta) in Patients With End Stage Renal Disease.

Anemia

Serbia
Hoffmann-La Roche

Completed

A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia

Anemia

Turkey
Centre Hospitalier Universitaire, Amiens
Roche Pharma AG

Completed

Effect of Epoetin Beta on Renal Function Within 30 Days Following a Kidney Transplant (Neo-PDGF)

Kidney Failure

France
University Hospital, Basel, Switzerland

Completed

Hemoglobin Kinetics in Response to Mircera® in Patients With Acute Myocardial Infarction (BEATSTEMIPi)

Acute Myocardial Infarction

Switzerland
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech, Inc.

Completed

A Study to Confirm the Safety and Efficacy of Epoetin Alfa (PROCRIT) Administered Perioperatively vs. the Standard of Care in Blood Conservation in Patients Undergoing Major Elective Spinal Surgery (SPINE Study)

Anemia | Venous Thrombosis
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.

Kidney Diseases | Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Determine the Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Non-anemic Patients Who Are Undergoing Orthopedic, Heart and Blood Vessel, or Breast Reduction Surgery; Performed in Combination With a Procedure to Reduce Blood Loss During Surgery.

Blood Transfusion | Orthopedic Surgery | Orthopedic Procedures | Mammaplasty | Cardiovascular Surgical Procedures | Blood Transfusion, Autologous
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy

Cancer | Anemia | Epoetin Alfa
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Undergoing Orthopedic Surgery and Who Have Low Hematocrit Levels (the Percent of Red Blood Cells in Whole Blood)

Anemia | Blood Transfusion | Orthopedic Procedures
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Anemia | Lung Cancer

United States
Chugai Pharmaceutical

Completed

Clinical Study of R744 to Hemodialysis Patients

Hemodialysis Patients

Japan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease

Anemia

United States, Puerto Rico
Hoffmann-La Roche

Completed

A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Participants With Chronic Renal Anemia in Pre-Dialysis or Dialysis (ALTITUD)

Anemia, Kidney Disease, Chronic

Mexico
Hoffmann-La Roche

Completed

A Study of Once Monthly Subcutaneous Mircera in Patients With Chronic Renal Anemia Not on Dialysis

Anemia

Korea, Republic of
Hoffmann-La Roche

Completed

A Study of Mircera in Renal Anemia Among Filipino Chronic Kidney Disease Patients

Anemia

Philippines
Hoffmann-La Roche

Completed

A Study of Monthly Subcutaneous Continuous Erythropoietin Receptor Activator (CERA) in Predialysis Participants With Chronic Renal Anemia (ORION)

Anemia

Italy
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Pharmacokinetic/ Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Critically Ill Patients.

Critical Illness | Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Research Into the Treatment of Anemia for Critically Ill Patients Admitted to Intensive Care Units (ICU)

Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Completed

A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.

Anemia | Chronic Kidney Disease
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Effectiveness and Safety of Epoetin Alfa During the Period When One is Donating One's Own Blood Before Surgery.

Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Safety of Epoetin Alfa and Its Effectiveness in Facilitating the Presurgical Collection of Blood From Anemic Patients for Possible Self-transfusion During and After Scheduled Joint Surgery.

Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy

Cancer | Anemia

United States
Janssen-Ortho Inc., Canada
Ontario Clinical Oncology Group (OCOG)

Completed

Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.

Carcinoma | Prostate
University Hospital, Basel, Switzerland
Roche Pharma AG

Completed

Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents (ESA)

Renal Anemia

Switzerland
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Epoetin Alfa in Treating Anemia in Patients With Solid Tumors

Lymphoma | Leukemia | Anemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Lymphoproliferative Disorder

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

Lymphoma | Leukemia | Breast Cancer | Chronic Myeloproliferative Disorders | Anemia | Small Intestine Cancer | Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Drug/Agent Toxicity by Tissue/Organ

United States, Canada
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Terminated

A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

Myelodysplastic Syndromes | Anemia

3

Subscribe